ProciseDx has developed a point-of-care platform that delivers lab-quality quantitative results in a remarkably short timeframe of 2 to 5 minutes. Utilizing advanced technologies such as time-resolved fluorescence resonance energy transfer (tr-FRET) and proprietary Lumiphore™ technology, the platform enables gastroenterologists to make informed treatment decisions during patient visits without sacrificing accuracy. The system is designed for ease of use, requiring only a finger-prick sample and minimal staff training, making it suitable for various healthcare settings. The platform has received CE Mark and FDA clearance for several assays, including those for infliximab, adalimumab, and C-reactive protein (CRP), ensuring compliance with regulatory standards.

The ProciseDx technology is optimized for quantitative immunoassays, allowing healthcare professionals to obtain immediate diagnostic answers that facilitate timely clinical actions. The system is versatile, compatible with multiple specimen types such as whole blood, serum, plasma, urine, saliva, and stool samples. By integrating established chemistry with proprietary compounds, ProciseDx enhances the speed and accuracy of diagnostic testing, ultimately improving patient care and outcomes. This innovative approach transforms patient appointments into productive sessions where immediate treatment decisions can be made based on reliable data.

United States

ProciseDx is helping patients leave appointments with answers instead of just another appointment.  Our point-of-care diagnostic solutions are enabling faster decisions for patients and physicians.

ProciseDx

Company Details